Philip D. Gregory - 11 Nov 2021 Form 4 Insider Report for bluebird bio, Inc. (BLUE)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
17 Nov 2021, 07:58:15 UTC
Prior SEC filing
08 Nov 2021
Next SEC filing
11 Jan 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Helen Fu, Attorney-in-Fact

Key filing fact

Philip D. Gregory filed Form 4 for bluebird bio, Inc. (BLUE) on 17 Nov 2021.

Key facts

  • This page summarizes Philip D. Gregory's Form 4 filing for bluebird bio, Inc. (BLUE).
  • 13 reported transactions and 7 derivative rows are listed below.
  • Accepted by SEC: 17 Nov 2021, 07:58.

Change

  • Previous filing in this sequence was filed on 08 Nov 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
+2,092
Change %
+9.8%
Price
$0.000000
Shares after
23,420
Date
11 Nov 2021
Ownership
Direct
Footnotes
F1, F2, F3
BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
+3,323
Change %
+14%
Price
$0.000000
Shares after
26,743
Date
11 Nov 2021
Ownership
Direct
Footnotes
F2, F3, F4
BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
+7,384
Change %
+28%
Price
$0.000000
Shares after
34,127
Date
11 Nov 2021
Ownership
Direct
Footnotes
F2, F3, F5
BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
0
Change %
0%
Price
$0.000000*
Shares after
34,127
Date
11 Nov 2021
Ownership
Direct
Footnotes
F2, F3, F6
BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
0
Change %
0%
Price
$0.000000*
Shares after
34,127
Date
11 Nov 2021
Ownership
Direct
Footnotes
F2, F3, F7
BLUE transaction

Common Stock

Other

Transaction value
$0
Shares
0
Change %
0%
Price
$0.000000*
Shares after
34,127
Date
11 Nov 2021
Ownership
Direct
Footnotes
F2, F3, F8

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLUE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-50,000
Change %
-50%
Price
$0.000000
Shares after
49,227
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
49,227
Exercise price
$81.23
Footnotes
F9
BLUE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-6,200
Change %
-50%
Price
$0.000000
Shares after
6,103
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,103
Exercise price
$25.16
Footnotes
F10
BLUE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-25,000
Change %
-50%
Price
$0.000000
Shares after
24,613
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
24,613
Exercise price
$37.66
Footnotes
F11
BLUE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-34,000
Change %
-50%
Price
$0.000000
Shares after
33,474
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
33,474
Exercise price
$102.24
Footnotes
F12
BLUE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-27,000
Change %
-50%
Price
$0.000000
Shares after
26,582
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
26,582
Exercise price
$67.06
Footnotes
F13
BLUE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-20,000
Change %
-50%
Price
$0.000000
Shares after
19,690
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
19,690
Exercise price
$36.78
Footnotes
F14
BLUE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
$0
Shares
-25,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0
Exercise price
$0.000000
Footnotes
F15
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Philip D. Gregory is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 15 footnotes

Footnote F1

Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on February 1, 2018 and vests over a four-year period at a rate of 25% on 01/04/2019, 25% on 01/04/2020, 25% on 01/04/2021, and 25% on 01/04/2022.

Footnote F2

bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP").

Footnote F3

bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP.

Footnote F4

Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on February 1, 2019 and vests over a four-year period at a rate of 25% on 01/04/2020, 25% on 01/04/2021, 25% on 01/04/2022, and 25% on 01/04/2023 .

Footnote F5

Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on March 2, 2020 and vests over a four-year period at the rate of 25% on 01/04/2021, 25% on 01/04/2022, 25% on 01/04/2023, and 25% on 01/04/2024.

Footnote F6

Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on February 16, 2021 and vests over a four-year period at a rate of 25% on 01/04/2022, 25% on 01/04/2023, 25% on 01/04/2024, and 25% on 01/04/2025.

Footnote F7

Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on August 2, 2021 and vests over a two-year period at the rate of 40% on August 2, 2022 and 60% on August 2, 2023.

Footnote F8

Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on August 2, 2021 and vests upon the satisfaction of certain performance criteria.

Footnote F9

Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on July 1, 2015 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.

Footnote F10

Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 1, 2016 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described footnotes 2 and 3.

Footnote F11

Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2017 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.

Footnote F12

Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2018 and vests over a four-year period, at a rate of 25% on 01/04/2019 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.

Footnote F13

Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 1, 2019 and vests over a four-year period, at a rate of 25% on 01/04/2020 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.

Footnote F14

Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on March 2, 2020 and vests over a four-year period, at a rate of 25% on 01/04/2021 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.

Footnote F15

Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on February 16, 2021 and vests over a four-year period, at a rate of 25% on 01/04/2022 and in 36 equal monthly installments thereafter. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .